Healthcare · NYSE/NASDAQ: DHR
DANAHER CORP /DE/
Diagnostics & Research
Market Cap $128.18B
Verdict: Exceptional
Quality Scores
Multi-Bagger
85/100
Compounder Quality
93/100
Management Credibility
92/100
Governance
95/100
Cash Flow Quality
95/100
AI Summary
Danaher Corporation (DHR) exemplifies an elite compounding machine, transitioning from a diversified industrial conglomerate to a pure-play Life Sciences and Diagnostics powerhouse. Over the last decade, the company successfully executed the 'Danaher Business System' (DBS) to integrate multi-billion dollar acquisitions like Cytiva (GE Biopharma) and Abcam, while spinning off lower-margin industrial units like Fortive and Veralto. Despite the post-pandemic normalization in COVID-related diagnostic volumes seen in 2023-2024, the core bioprocessing and clinical diagnostics businesses remain…
Top Opportunities
- Consistent Cash Flow from Operations (OCF) generation
- Successful execution of the Veralto spin-off (September 2023)
- Strong application of Danaher Business System (DBS) for efficiency
Top Risks
- Significant revenue drop in 2023 due to restructuring
- Net income declining for three consecutive years (2022-2025)
- Substantial goodwill and intangibles on balance sheet from M&A
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.